InterVenn Biosciences and Aranscia Expand Commercialization Partnership for GlycoKnow™ Ovarian Cancer Diagnostic Test

InterVenn Biosciences, a life sciences company unlocking the value of glycoproteomics for the development of transformational healthcare solutions, and Aranscia, a global provider of award-winning clinical workflow and diagnostic technology solutions, today announced an expansion of their commercialization partnership to broaden access to InterVenn’s flagship GlycoKnow™ Ovarian cancer diagnostic test for clinicians and researchers.